 |
|
Prospects for Vascular Endothelial Growth Factor Neurotherapeutics
Arch Neurol. 2002;59:692-694.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
VASCULAR ENDOTHELIAL growth factor (VEGF) plays an essential role in
the growth of new blood vessels, contributes to the regulation of blood flow
and vascular permeability, and has direct trophic effects on many cell types
in addition to endothelium, including neurons and glia.1-5
Tissue hypoxia enhances local VEGF synthesis, leading to increased vascularity
of the hypoxic tissue.2, 6 Raising
tissue VEGF levels by administration of recombinant VEGF or VEGF DNA also
elicits neovascularization, and thus diminishes disability in animals with
central nervous system (CNS) or peripheral nerve ischemia and in patients
with coronary or limb arterial insufficiency. In experimental animals, VEGF
therapy enhances recovery from focal brain ischemia and from neuropathy caused
by ischemia or diabetes mellitus. Additional human VEGF trials can be anticipated
in diabetic neuropathy and CNS ischemia. Genetically engineered ablation in
mice of the transcriptional mechanism by which VEGF is induced by hypoxia
causes motor neuron degeneration. This . . . [Full Text of this Article]VEGF SYNTHESIS
BIOLOGICAL EFFECTS OF VEGF
VEGF SIGNALING
INDUCTION OF VEGF SYNTHESIS IN NEUROLOGICAL DISEASES
IS THERE A ROLE FOR VEGF THERAPY IN CNS ISCHEMIA?
VEGF THERAPY FOR TRAUMATIC, ISCHEMIC, AND DIABETIC NEUROPATHIES
CONCLUSIONS
Corresponding author: David Pleasure, MD, Room 516H Abramson Research
Bldg, The Children's Hospital of Philadelphia, 34th and Civic Center Boulevard,
Philadelphia PA 19104 (e-mail: pleasure@e-mail.chop.edu).
RELATED ARTICLE
Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2002;59(5):878-880.
FULL TEXT
|
